Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Decreases By 14.3%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 42,400 shares, a decrease of 14.3% from the May 31st total of 49,500 shares. Currently, 4.9% of the shares of the stock are short sold. Based on an average daily volume of 60,600 shares, the days-to-cover ratio is currently 0.7 days.

Avenue Therapeutics Stock Down 0.9 %

Shares of ATXI traded down $0.03 during mid-day trading on Tuesday, reaching $3.37. 15,581 shares of the company’s stock were exchanged, compared to its average volume of 66,793. Avenue Therapeutics has a 52-week low of $3.25 and a 52-week high of $93.75. The company has a market cap of $3.17 million, a price-to-earnings ratio of -0.43 and a beta of -0.19. The company has a 50-day simple moving average of $4.01 and a two-hundred day simple moving average of $8.89.

Avenue Therapeutics (NASDAQ:ATXI) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($15.40) earnings per share for the quarter.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.